A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer

A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer

Abstract Background Docetaxel (D) or secondary hormonal therapy (SHT) each combined with androgen deprivation therapy (ADT) represent possible treatment options in males with metastasized hormone‐sensitive prostate cancer (mHSPC). Real‐world data comparing different protocols are lacking yet. Thus,...

Full description

Bibliographic Details
Main Authors: Igor Tsaur, Isabel Heidegger, Jasmin Bektic, Mona Kafka, Roderick C. N. van denBergh, Jarmo C. B. Hunting, Anita Thomas, Maximilian P. Brandt, Thomas Höfner, Eliott Debedde, Constance Thibault, Paola Ermacora, Fabio Zattoni, Silvia Foti, Alexander Kretschmer, Guillaume Ploussard, Severin Rodler, Gunhild vonAmsberg, Derya Tilki, Christian Surcel, Barak Rosenzweig, Moran Gadot, Giorgio Gandaglia, Robert Dotzauer, EAU‐YAU Prostate Cancer Working Party
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Cancer Medicine
Subjects:
chemotherapy
hormonal therapy
hormone‐sensitive
metastasis
prostate cancer
Online Access:https://doi.org/10.1002/cam4.4184

Internet

https://doi.org/10.1002/cam4.4184

Similar Items